Dr Scott Kopetz speaks to ecancer about the BREAKWATER progression-free survival and updated overall survival analyses.

The BREAKWATER study examines the combination of encorafenib and cetuximab with chemotherapy for metastatic BRAF V600E colorectal cancer.

The study included 637 patients and compared an experimental arm to a control arm, with the experimental arm showing a 65.7% response rate and a median progression-free survival of 12.8 months.

This was significantly better than the control arm.

Dr Kopetz highlights that the safety data indicates no major adverse events, leading to accelerated approval and future research on treatment mechanisms.